CommercialCoverageMedium impact
11.07.01ac, Hematopoietic Stem Cell Transplantation
Independence Blue Cross·Hematology, Oncology, Transplant Surgery +1 more·Medical Policy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross added Filgrastim-txid (Nypozi) as a medically necessary Colony-Stimulating Factor for hematopoietic stem cell transplantation coverage under policy 11.07.01ad, effective 10/20/2025. Additionally, all references to related drug policies were reorganized from the Policy Section to the Cross Reference Policies section for improved clarity.
Action Required
By October 20, 2025: Billing team must update billing system configuration to recognize C9173 (Filgrastim-txid/Nypozi) as a covered medically necessary drug under hematopoietic stem cell transplantation procedures. Update prior authorization workflows and claim scrubbing rules to allow C9173 submission alongside hematopoietic stem cell transplantation CPT codes (38240, 38241) and related mobilization/harvesting codes (38204-38208). Providers should update encounter templates and care pathways to reflect Nypozi as an approved colony-stimulating factor option. Update internal policy reference documents to direct staff to the Cross Reference Policies section for related drug policies (filgrastim, Efbemalenograstim alfa-vuxw). Verify that system updates are complete before the effective date to prevent claim denials for C9173 claims submitted on or after October 20, 2025.